Selective decrease of donor-reactive Tregs after liver transplantation limits Treg therapy for promoting allograft tolerance in humans

Qizhi Tang, Joey Leung, Yani Peng, Alberto Sanchez-Fueyo, Juan Jose Lozano, Alice Lam, Karim Lee, John R. Greenland, Marc Hellerstein, Mark Fitch, Kelvin W. Li, Jonathan H. Esensten, Amy L. Putnam, Angela Lares, Vinh Nguyen, Weihong Liu, Nancy D. Bridges, Jonah Odim, Anthony J. Demetris, Josh LevitskyTimucin Taner, Sandy Feng

Research output: Contribution to journalArticlepeer-review


Promoting immune tolerance to transplanted organs can minimize the amount of immunosuppressive drugs that patients need to take, reducing lifetime risks of mortality and morbidity. Regulatory T cells (Tregs) are essential for immune tolerance, and preclinical studies have shown their therapeutic efficacy in inducing transplantation tolerance. Here, we report the results of a phase 1/2 trial (ARTEMIS, NCT02474199) of autologous donor alloantigen–reactive Treg (darTreg) therapy in individuals 2 to 6 years after receiving a living donor liver transplant. The primary efficacy endpoint was calcineurin inhibitor dose reduction by 75% with stable liver function tests for at least 12 weeks. Among 10 individuals who initiated immunosuppression withdrawal, 1 experienced rejection before planned darTreg infusion, 5 received darTregs, and 4 were not infused because of failure to manufacture the minimal infusible dose of 100 × 106 cells. darTreg infusion was not associated with adverse events. Two darTreg-infused participants reached the primary endpoint, but an insufficient number of recipients were treated for assessing the efficacy of darTregs. Mechanistic studies revealed generalized Treg activation, senescence, and selective reduction of donor reactivity after liver transplantation. Overall, the ARTEMIS trial features a design concept for evaluating the efficacy of Treg therapy in transplantation. The mechanistic insight gained from the study may help guide the design of future trials.

Original languageEnglish (US)
Article numbereabo2628
JournalScience translational medicine
Issue number669
StatePublished - Nov 2 2022

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Selective decrease of donor-reactive Tregs after liver transplantation limits Treg therapy for promoting allograft tolerance in humans'. Together they form a unique fingerprint.

Cite this